Skip to main content
MLYS
NASDAQ Life Sciences

Mineralys Q3 Loss Widens to $57.3M as Launch Spending Builds; $624.7M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.82
Mkt Cap
$1.503B
52W Low
$15.33
52W High
$47.65
52W Position info
9.7% above low
Off High info
65% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MLYS is trading near its 52-week low of $15.33 (9.7% above the low).

Summary

Mineralys posted a $57.3M Q3 loss as commercialization spending ramped, with $624.7M in cash and investments ahead of the December 22, 2026 FDA decision on lorundrostat.


Key Events · Earnings and Guidance · MLYS

  • Q3 Loss Widens on Launch Spending

    Net loss of $57.3M ($0.64 per share) versus $36.9M ($0.52) in Q3 2025. G&A rose to $37.4M from $9.7M on commercialization headcount and professional fees, while R&D fell $8.8M to $22.7M as the pivotal program concluded.

  • Cash Covers Launch; Debt Tied to Approval

    Cash, cash equivalents and investments totaled $624.7M at September 30, 2026, with $187.2M still available under the ATM and $400M of undrawn term-loan tranches. The $150M Tranche B draw requires FDA approval of the lorundrostat NDA; if not met by September 30, 2027, four $25M quarterly repayments begin and maturity accelerates to June 30, 2028.

  • Tanabe License Terminated, Patents Owned

    The October 27, 2026 termination assigns all lorundrostat IP rights to Mineralys with no material penalty, but up to $255.0M of commercial milestones remain payable, plus up to $10.0M for a second indication.

  • FDA Decision Due December 22, 2026

    The lorundrostat NDA for hypertension has a PDUFA target date of December 22, 2026; the company is staffing commercial functions in anticipation of approval.


Analysis · MLYS · Life Sciences

The quarterly loss widened to $57.3M from $36.9M a year ago, driven almost entirely by the pre-commercial build-out: G&A jumped to $37.4M from $9.7M as the company staffs sales, market access and medical affairs ahead of the December 22, 2026 FDA decision on lorundrostat. R&D actually fell $8.8M as the pivotal program wound down. With $624.7M in cash and investments, plus $187.2M still available under the ATM and $400M of undrawn term-loan tranches, funding through launch is not in question — but the burn rate is now the number that matters, and the Tranche B $150M draw is contingent on FDA approval. The 10-Q also confirms the October 27 Tanabe termination that hands Mineralys direct ownership of the lorundrostat patents while leaving up to $255M of commercial milestones payable.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLYS was trading at $16.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $15.33 to $47.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLYS - Latest Insights

MLYS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.16
Real-time Price: $14.05 info
Change: -$3.11 (-18%) info
Market Cap: $1.22B info
MLYS
Oct 29, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.24
Real-time Price: $14.05 info
Change: -$7.19 (-34%) info
Market Cap: $1.22B info
MLYS
Oct 28, 2026, 7:05 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.30
Real-time Price: $14.05 info
Change: -$7.25 (-34%) info
Market Cap: $1.22B info
MLYS
Oct 22, 2026, 6:40 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.47
Real-time Price: $14.05 info
Change: -$7.42 (-35%) info
Market Cap: $1.22B info
MLYS
Oct 09, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $22.35
Real-time Price: $14.05 info
Change: -$8.30 (-37%) info
Market Cap: $1.22B info